English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Gene Therapy Improves Muscle Function for Children With Spinal Muscular Atrophy
Children with spinal muscular atrophy (SMA) carry specific gene defects which cause progressive muscle wasting and weakness. Left untreated, the condition usually results in early death. Approval was recently granted for a gene replacement therapy that enables the maintenance of muscle function. However, due to the treatment’s relative novelty, data on safety and efficacy remain limited.
A team from Charité – Universitätsmedizin Berlin recently conducted the first multicenter clinical study to evaluate data on the side effects associated with this new gene replacement therapy. Their study showed that treatment resulted in significant improvement in muscle function, particularly in children under two years of age. The researchers’ findings have been published in The Lancet Child & Adolescent Health.
BookmarkRelated Content
-
Jerry R. Mendell, MDJerry R. Mendell, MD, is an Attending Ne...
-
Will Parental Vaccine Hesitancy Retard the Embrace of Life-Saving Newborn Genetic Screening and Emerging Gene Therap...In these days of the never-ending pandem...
-
Thomas Crawford, MDDr. Tom Crawford has been a member of th...
-
Jessica Nance, MD, MSDr. Jessica Nance, treats pediatric pati...
-
Newborn Screening, Treatment Make Big Difference With Rare Muscle DisorderMateo Medina has never walked or talked....
-
STR1VE-EU Trial Shows Efficacy of Onasemnogene Abeparvovec in Spinal Muscular AtrophyOnasemnogene abeparvovec gene replacemen...
-
Implications of Circulating Neurofilaments for Spinal Muscular Atrophy Treatment Early In Life: A Case SeriesThis longitudinal cohort study aimed to ...
Powered by
In partnership with
